Absci

Absci Equity Ratio

The Equity Ratio of Absci (ABSI) as of Oct 17, 2026 is 87.59 %. In the previous year, Equity Ratio was 83.86 % — a change of 4.44% (higher).

Equity Ratio

87.59 %

YoY

4.44%

Last updated:

Equity Ratio of Absci is 2025 87.59 % . Equity Ratio of Absci was 2024 83.86 % . It decreases by 4.44% higher compared to the previous year.

The Absci Equity Ratio history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity Ratio
Date
Equity Ratio
Jan 1, 2019
-211.39 USD
Jan 1, 2020
75.65 USD
Jan 1, 2021
85.90 USD
Jan 1, 2022
85.49 USD
Jan 1, 2023
81.08 USD
Jan 1, 2024
83.86 USD
Jan 1, 2025
87.59 USD
The Absci Equity Ratio history
YEAREquity RatioYoY
87.59 %+4.44%
83.86 %+3.43%
81.08 %-5.16%
85.49 %-0.48%
85.90 %+13.55%
75.65 %-135.79%
-211.39 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Absci Stock analysis

What does Absci do? Absci Corp, trading under the ticker ABSI with ISIN US00091E1091, is a biotechnology company headquartered in Vancouver, Washington, operating within the Health Care sector. The company went public via an IPO on July 22, 2021. Absci employs 140 people. It leverages artificial intelligence and synthetic biology to explore and expand the therapeutic potential of proteins. The company utilizes a platform combining AI with scalable wet lab technologies to develop biologics for patients. Absci's approach involves identifying novel drug targets, discovering biotherapeutic candidates, and generating cell lines for manufacturing within a single integrated process. The firm applies generative AI to design drug candidates optimized for target affinity, safety, manufacturability, and other characteristics. Absci's technology includes SoluPro, a multiplex synthetic biology method that addresses limitations of high-throughput automation labs. The company supports its AI-driven designs with high-throughput functional validation capabilities in its wet lab. Absci's website is www.absci.com, providing information about its services and technology. The company focuses on creating biologic drug candidates for partners, using data generated from its processes to refine and improve its platform. Absci is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Absci stock

Equity Ratio of Absci is 87.59 % in 2025.

Equity Ratio of Absci changed from 83.86 % to 87.59 %, representing a 4.44% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Equity Ratio Absci since 2006 – with annual values, charts, and detailed analysis.

The equity ratio measures the proportion of total assets financed by shareholders' equity. Higher ratios indicate stronger financial independence and lower leverage.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Equity Ratio's Absci with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Absci

All Key Metrics — Absci